anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Unlike other studies in the literature, this designed study evaluates balance, functionality, anxiety, cognitive functions and quality of life in addition to walking, making it unique. In the light of all this information, the hypothesis of the study is as follows: Application of dual-task-oriented training in addition to the regular physiotherapy program in individuals with chronic stroke affects balance, functionality, anxiety levels, cognitive functions and quality of life. It is planned to include 40 participants who meet the inclusion criteria in the study. After giving the necessary verbal and written information about the study, participants who receive informed consent will be randomized and divided into 2 groups of 20 people each. Group 1 will receive 30 sessions of traditional neurological rehabilitation program every day for 6 weeks. In Group 2, in addition to traditional neurological rehabilitation, a dual-task-oriented training program will be applied for a total of 12 sessions, twice a week. Participants will be evaluated twice, before and after treatment. Researchers will record personal information through a socio-demographic data form. Balance will be evaluated with the Berg Balance Test, functional status will be evaluated with the 10 Meter Walk Test and Timed Up and Go Test, anxiety level will be evaluated with the Beck Anxiety Scale, cognitive functions will be evaluated with the Verbal Fluency Test, and Standardized Mini Mental Test and quality of life will be evaluated with the Stroke Specific Quality of Life Scale.
Particular care is needed for patients who have been transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although budesonide and formoterol fumarate dihydrate may provide control of asthma symptoms during these episodes, in recommended doses it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.

During periods of stress, a severe asthma attack or a severe COPD exacerbation, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress, a severe asthma attack, or a severe COPD exacerbation.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to budesonide and formoterol fumarate dihydrate. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with budesonide and formoterol fumarate dihydrate. Lung function (mean forced expiratory volume in 1 second [FEV1] or morning peak expiratory flow [PEF]), beta-agonist use, and asthma or COPD symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to inhaled corticosteroids or budesonide and formoterol fumarate dihydrate may unmask conditions previously suppressed by the systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions). Some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.
Transition metals such as copper and iron, alone or in combination with each other or other transition metals, in aqueous solution are able to inactivate bacteria fungi, and viruses with an efficiency similar to that of substances usually recommended for disinfection and sterilization. Other transition metals can be used as disinfectant and sterilizing agents. The inactivating efficiency of such metals can be greatly enhanced by the addition of hydrogen peroxide, other peroxides, or pero-generating agents. The microbicidal potency of such mixtures can be increased even further in a ternary system composed of metal(s), peroxide, and a chelator, such as nitrilotriacetic acid (NTA). Different formulations of mixtures of metals and peroxide with or without NTA are provided. These are capable of inactivating viruses, bacteria, and fungi with an efficiency higher than that exhibited by substances currently in use. Also provided are methods for inactivating microorganisms for vaccine development, sterilizing or disinfecting medical devices and fluids, treating infectious disease, and assaying disinfectant, sterilizing, and antimicrobial substances and complex mixtures for microbicidal efficiency.
Standard procedure for residential treatment program. Includes: supportive group therapy; Narcotics Anonymous/12-Step Programming; music, art, and animal therapy; psycho-education on issues related to mental health and substance use disorders; and medication counseling. No aspect of the treatment-as-usual services provided entails mindfulness training or components of mindfulness training.
The invention relates to a hematopoietic targeted helper adenovirus and application thereof, belonging to the field of biotechnologies and gene therapy. The invention comprises the construction and the preparation of the hematopoietic targeted helper adenovirus, the preparation, the amplification and the purification of helper-dependent adenoviral vectors (HD-Ad) and the verification of hematopoietic targeting function. A packaging signal carried by the helper adenovirus is an incomplete packaging signal, both ends of the packaging signal contain loxp sequences, homologous recombination can be carried out under the action of a Cre recombinase, and the packaging signal is cut off to further reduce the production of helper adenovirus and improve the yield and the quality of the target virus. A skeleton plasmid of the helper adenovirus is pAd5/F11p, and a fiber top ball changed from the skeleton plasmid can enable the helper adenovirus to have hematopoietic targeting characteristic. The HD-Ad prepared by using the helper adenovirus has the particle characteristics of helper adenovirus and can effectively target hematopoietic cells. Thus, the invention provides an experiment basis and a theoretical basis for the application of HD-Ad in hematopoietic cell gene therapy.
Systemic evaluation of dose and/or interval between dose has not been done. However, on limited clinical experience, the recommended initial dose of Syprine is 500-750 mg/day for pediatric patients and 750-1250 mg/day for adults given in divided doses two, three or four times daily. This may be increased to a maximum of 2000 mg/day for adults or 1500 mg/day for pediatric patients age 12 or under.

The daily dose of Syprine should be increased only when the clinical response is not adequate or the concentration of free serum copper is persistently above 20 mcg/dL. Optimal long-term maintenance dosage should be determined at 6-to 12-month intervals (see PRECAUTIONS, Laboratory Tests).

It is important that Syprine be given on an empty stomach, at least one hour before meals or two hours after meals and at least one hour apart from any other drug, food, or milk. The capsules should be swallowed whole with water and should not be opened or chewed.
A method for the complex treatment and prevention in pregravidal preparation of the patients with history of reproductive losses and hyperandrogynism provides for the complex treatment. The gastrointestinal tract is examined and the treatment aimed at detoxification of the body is provided. First, the etiological factors contributing to the pathology of the gastrointestinal tract are eliminated and the balanced alimentation is provided. At the second step, the drugs restoring or substituting the secretory activity of the gastric glands. At the third step, the intestine is colonized with synergic intestinal lacto- or bifidobacteria and the drugs increasing activity of conjugating enzymes are provided. Finally, the reparation processes in the intestine are stimulated and the secretion of steroid hormones of reproductive system is restored (luteinizing hormone and follicle-stimulating hormone). The duration of the treatment is 2-6 months depending on the state of the patient and the concomitant pathology.
PURPOSE:An appropriate amount of decocted mugwort it taken arbitrary times a day to cure cancers. CONSTITUTION:A handful of mugwort, preferably its stems, in particular, mugwort stems collected in autumn (of 8mm. or more diameter) is finely cut with a mixer, when desired, then decocted to prepare a solution. The decocted solution is taken several times a day, e.g., every meal or after breakfast and supper by an appropriate amount, e.g., one tea cup to cure cancers. Overdoes raises blood pressure and the appropriate amount should be found. The decocted mugwort is effective against not only uterine cancer but also other cancers and hemostasis.
The present invention provides a recombinant matrix protein of Nipah virus containing matrix protein of Nipah virus which includes at least one His tag and myc epitope. Further, the present invention also provides a recombinant plasmid including recombinant matrix protein of Nipah virus. Also provided is a method for producing recombinant matrix protein of Nipah virus which includes the steps of (a) culturing expression host containing expression vector of recombinant matrix protein in a medium which allows growth of the expression host, (b) allowing the recombinant matrix protein to be expressed in the expression host, (c) harvesting the expression host from step (b) from the medium, (d) disrupting the expression host harvested from step (c) in a medium for sonication purposes and (e) purifying the recombinant matrix protein obtained from step (d). Also provided is a method for purifying recombinant matrix protein of Nipah virus which includes the steps of (a) harvesting and lysing recombinant expression host containing recombinant matrix protein cells, (b) purifying the recombinant matrix protein using nickel affinity column chromatography, (c) dialyzing the purified recombinant matrix protein from step (b) with buffer solution, (d) fractionating the purified recombinant matrix protein from step (c) using centrifugation and (e) collecting and pooling the fractionated recombinant matrix protein obtained from step (d) concentration of protein. There is also provided a pharmaceutical composition comprising a therapeutically effective amount of recombinant matrix protein of Nipah virus. Also provided is a diagnostic reagent comprising an effective amount of recombinant matrix protein matrix protein of Nipah virus.
PURPOSE: Annually, over 20 million patients worldwide undergo inguinal hernia repair procedures. Surgery stands as the recommended treatment, however, a consensus on the optimal method is lacking. This study aims to conduct an updated systematic review and meta-analysis to compare the risk of chronic inguinal pain and recurrence between laparo-endoscopic mesh repair (TAPP and TEP) versus Lichtenstein repair for inguinal hernia.
METHODS: Searches were conducted in Ovid MEDLINE, PubMed, EBSCO, Cochrane, and Google Scholar. Inclusion criteria encompassed randomized controlled trials (RCTs) involving adults, published in English and Spanish, comparing surgical outcomes among the Lichtenstein open technique, TAPP, and/or TEP. Adherence to the PRISMA guidelines was maintained in the methodology, and the CASP tool was employed to assess the quality of the articles. Statistical analysis involved mean [± standard deviation (SD)], Odds Ratio (OR), and Confidence Interval (CI).
RESULTS: Eight RCTs encompassing 1,469 patients randomized to Lichtenstein repair (n = 755) and laparo-endoscopic repair (n = 714) were included. Laparo-endoscopic repair was associated with a lower likelihood of chronic inguinal pain compared to Lichtenstein repair (OR = 0.28, 95% CI [0.30-0.56], p = 0.0001). There were no significant differences in recurrence rates between the laparo-endoscopic and the Lichtenstein group (OR = 1.03, 95% CI [0.57-1.86], p = 0.92).
CONCLUSIONS: This systematic review and meta-analysis demonstrate that laparo-endoscopic hernia surgery leads to a lower incidence of chronic inguinal pain compared to Lichtenstein repair, while maintaining similar rates of recurrence.
PURPOSE: To provide a transparent leave-on hair treatment compsn. formed by encapsulating a hair treatment compd. insoluble in water into capsules. CONSTITUTION: The transparent leave-on hair treatment compsn. contains (i) the capsules formed by encapsulating the conditioning compd. insoluble in the water into a shell material, (ii) a settlement preventing agent for suspending the capsules and (iii) a carrier contg. the water. The hair treatment compd. insoluble in the water is released from the capsules, by which the hair is treated when or after the compsn. is applied to the hair. The residual shell fragments of the capsules are sufficiently small and do not adversely affect the physical and aesthetic characteristics.
Fanconi anemia (FA) is an autosomal or X-linked human disease, characterized by bone marrow failure, cancer susceptibility and various developmental abnormalities. So far, at least 22 FA genes (FANCA-W) have been identified. Germline inactivation of any one of these FA genes causes FA symptoms. Proteins encoded by FA genes are involved in the Fanconi anemia pathway, which is known for its roles in DNA inter-strand crosslinks (ICLs) repair. Besides, its roles in genome maintenance upon replication stress has also been reported. Post-translational modifications (PTMs) of FA proteins, particularly phosphorylation and ubiquitination, emerge as critical determinants in the activation of the FA pathway during ICL repair or replication stress response. Consequent inactivation of the FA pathway engenders heightened chromosomal instability, thereby constituting a genetic susceptibility conducive to cancer predisposition and the exacerbation of tumorigenesis. In this review, we have combined recent structural analysis of FA proteins and summarized knowledge on the functions of different PTMs in regulating FA pathways, and discuss potential contributions stemming from mutations at PTMs to the genesis and progression of tumorigenesis.
PURPOSE: Patients with arteriovenous malformations (AVMs) have a lower health-related quality of life (QoL) than the general population. QoL assessment of patients with peripheral AVMs after endovascular treatment is scarce in the literature. Radiologic and clinical outcomes are not always correlated in vascular malformation treatment. This study aimed to investigate the relationship between clinical outcomes, QoL, and angiographic outcomes.
MATERIALS AND METHODS: Patients with peripheral AVM that underwent endovascular treatment between January 2009 and December 2021 in a single center were retrospectively evaluated. Patients' characteristics (age, sex), AVM characteristics (Schobinger classification, location, angiographic architecture), previous treatment, treatment characteristics (type of endovascular approach, embolizing agent and number of sessions), percentages of angiographic response, complications, and recurrence were evaluated. The angiographic architecture was evaluated according to the Yakes classification. The questionnaire was applied for evaluation of clinical response and QoL. Patients older than 12 years and those who can be contacted were included in clinical and QoL analysis. Clinical response was defined as improvement in the patient's most important pretreatment symptom. Treatment response was defined as clinical response plus >50% angiographic response.
RESULTS: Eighty-six patients (41 males [47.7%], 45 females [52.3%]) were included in angiographic analysis. The mean age was 28.44±12.99 years (range=5-61). Forty-three patients (50%) had previous treatment. The median number of sessions was 2 (range 1-15, InterQuartile Range [IOR]=2). Sixty-one patients (30 males [49.2%], 31 females [50.8%]) were included in clinical analysis. The clinical response rate was 73.8%, 95% confidence interval (CI) [0.60, 0.84]. The treatment response rate was 45.9%, 95% CI [0.33, 0.59]. The complication rate was 8.2%. Before treatment, 48 patients (78.7%) reported a negative impact on their QoL. Thirty-three of 48 patients (68.8%) reported improvement on their QoL after treatment. Higher Schobinger stages were related to a negative impact on QoL before treatment (p<0.01). Yakes types were not related to QoL (p=0.065). Clinical response was related to improvement on QoL after treatment (p<0.01). Angiographic and treatment responses were not related to improved QoL after treatment (p=0.52 and p=0.055, respectively).
CONCLUSION: Angiographic architecture and outcomes were not always reflected in QoL after endovascular treatment.
CLINICAL IMPACT: This study's findings will help clinicians with what to focus on in AVM treatment and how to monitor patients with peripheral AVM after endovascular treatment. Rather than relying too much on the angiographic response, patients should be checked for symptoms and quality of life improvement. No clear data in the literature regarding the applicability of the Yakes Classification in patients with previous treatment. This study questioned the applicability of the Yakes Classification in patients with previous treatments. In this study, type 4 AVMs were more common in patients with previous treatment.
After successful screening the cases of cirrhosis of liver irrespective of the etiology who have non tumor portal vein thrombosis will be enrolled. The baseline parameter will be recorded and the patient will be randomized into either interventional (vagus nerve-preserving laparoscopic splenectomy and azygoportal disconnection) or control (conventional laparoscopic splenectomy and azygoportal disconnection) group. From postoperative day 3, all patients will receive 100 mg oral aspirin enteric-coated tablets (Bayer, Leverkusen, Germany) once daily for 1 year, low-molecular-weight heparin (CS Bio, Hebei, China) subcutaneously (4.100 IU/day) for 5 days, and 25 mg of oral dipyridamole (Henan Furen, Henan, China) thrice daily for 3 months. At months 3, 9, and 12 after operation, electron gastroscopy examination for delayed gastric emptying will be done for all patients. Postoperative complications of the digestive system (including diarrhea, epigastric fullness, bloating, nausea, and vomiting), liver and renal function, and body weight will be recorded at the seventh day, months 1, 3, 6, 9, and 12 after operation. Then one year monitoring will be done in the both groups as per the primary or secondary outcome.
PROBLEM TO BE SOLVED: To obtain a medicine harmonizing with immune system, symbiotically interacting, attacking pathogeny and symptom, free from side effect, useful for therapy of plaque on a tooth by including a proteolytic enzyme separated from krill. SOLUTION: This medicine includes a mixture of hydrase including an enzyme originating from krill. In a preferable example of a preparative method of this medicine, distilled water is added to white krill or Euphausia superba in a ratio of 1:1, adding 0.02% of sodium azide and leaving standing for 6 hr. at 4 deg.C. Then recovering aqueous phase by centrifugal separation and degreasing by adding ethyl acetate at 4 deg.C. Recovering lower side aqueous phase, boiling and adding saturated ammonium sulfate to saturated sate of 60%. Separating the product precipitate, dissolving in 0.05 mole phosphorus buffer solutiorl of 0.05 mole sodium chloride (PBS) at pH 7.4 and then extracting the material by dialyzing to PBS. Multiple enzymes and a single enzyme are recovered from the extracted material.
A prospective case series design will be adopted. Due to the small sample size and the preliminary nature of the study, a single case study or case series are classified under Observational Descriptive Studies. The investigators will seek local Institutional Review Board (IRB) approval. Ten volunteers who respond to the recruitment efforts will be enrolled into the study. Successful enrollment is based on strict inclusion and exclusion criteria. Brahmi oil (sesame oil processed with Bacopa monieri and other herbs) will be used to perform Shirodhara. Each participant will be treated for 40 minutes for five consecutive days. Outcome measures data will be collected at baseline, third day and fifth day and a week after the treatment is over. Additionally, demographic data will be collected at baseline as well. Participants will be asked to record any adverse events or side effects they observe during the study period.
The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
Miglitol was administered to mice by the dietary route at doses as high as approximately 500 mg/kg body weight (corresponding to greater than 5 times the exposure in humans based on AUC) for 21 months. In a two-year rat study, miglitol was administered in the diet at exposures comparable to the maximum human exposures based on AUC. There was no evidence of carcinogenicity resulting from dietary treatment with miglitol.

In vitro, miglitol was found to be nonmutagenic in the bacterial mutagenesis (Ames) assay and the eukaryotic forward mutation assay (CHO/HGPRT). Miglitol did not have any clastogenic effects in vivo in the mouse micronucleus test. There were no heritable mutations detected in dominant lethal assay. 

A combined male and female fertility study conducted in Wistar rats treated orally with miglitol at dose levels of 300 mg/kg body weight (approximately 8 times the maximum human exposure based on body surface area) produced no untoward effect on reproductive performance or capability to reproduce. Survival, growth, development, and fertility of the offspring were not compromised.